A Study in Healthy Volunteers Investigating How Quickly and to What Extent BAY1817080 is Taken up, Distributed, Broken Down and Eliminated From the Body, as Well as the Difference Between 2 Different Types of Tablets of BAY1817080 and the Difference Between Oral Dose and Dose in the Vein

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 13, 2018

Primary Completion Date

June 21, 2019

Study Completion Date

August 12, 2019

Conditions

Biological Availability

Interventions

DRUG

BAY1817080 - Formulation A

Formulation A

DRUG

BAY1817080 - Formulation B

Formulation B

DRUG

[13C715N]-BAY 181708 stable isotope label (SIL)

0.1 mg \[13C715N\]-BAY181708, 15 minutes i.v. infusion at the estimated tmax after administration of Formulation B

Trial Locations (1)

PRAHealthSciences, Groningen